Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Not yet recruiting 1Completed 1

Sponsor Class

OTHER 4INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 78Lung Neoplasms 17Neoplasms 14Carcinoma 9Neoplasm Metastasis 7Thoracic Neoplasms 4NSCLC 4Colorectal Neoplasms 4Respiratory Tract Neoplasms 3Respiratory Tract Diseases 3Neoplasms by Site 3Lung Diseases 3Bronchial Neoplasms 3Brain Neoplasms 3Squamous Cell Carcinoma of Head and Neck 2Solid Tumor 2Noonan Syndrome 2Neoplasms, Nerve Tissue 2Neoplasms by Histologic Type 2Meningeal Carcinomatosis 2Head and Neck Neoplasms 2Carcinoma, Bronchogenic 2Breast Neoplasms 2Adenocarcinoma 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1T790M Positive NSCLC Patients 1Stomach Neoplasms 1

Interventions

paclitaxel-Angiopep-2 conjugate 2osimertinib 2omburtamab I-131 2AZD3759 2eribulin 1XL647 1WP 744 1Methotrexate 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Meningeal Carcinomatosis × osimertinib × Clear all
NCT07361705 2026-01-23

Zorifertinib With Osimertinib for NSCLC With Meningeal Progression

Alpha Biopharma (Jiangsu) Co., Ltd.

Phase 1 Not yet recruiting
42 enrolled
CNS

Meningeal Carcinomatosis

NCT02228369 2021-01-05

BLOOM

AstraZeneca

Phase 1 Completed
108 enrolled
CNSThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Meningeal Carcinomatosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡